Mesoblast Ltd - ADR
NASDAQ:MESO 3:59:52 PM EDT
| Market Cap (Intraday) | 1.13B |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $8.57 |
| 50-Day MA | $9.30 |
| 200-Day MA | $12.35 |
Mesoblast Ltd. Stock, NASDAQ:MESO
55 Collins Street, Level 38, Melbourne, Victoria (VIC) 3000
Australia
Phone: +61.3.9639.6036
Number of Employees: 102
Description
Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. Its medicines target the cardiovascular diseases, spine orthopedic disorders, oncology and hematology, immune-mediated, and inflammatory diseases. The company was founded by Itescu Silviu on June 8, 2004 and is headquartered in Melbourne, Australia.